8QQ.F ABCELLERA BIOLOGICS
- Market cap
- EUR 3.87B
- P/E
- -
- P/B
- 3.75x
- ROE
- -17.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8QQ.F undervalued?
Graham numberThe Graham number of ABCELLERA BIOLOGICS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABCELLERA BIOLOGICS fundamental analysis
No fundamental analysis for ABCELLERA BIOLOGICS yet.
ABCELLERA BIOLOGICS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The …
Full company profileABCELLERA BIOLOGICS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ABCELLERA BIOLOGICS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 375M | 485M | 38.0M | 28.8M | 75.1M | 30.7M |
| Gross Profit | 330M | 419M | 38.0M | 28.8M | - | - |
| Operating Income | 222M | 227M | -223M | -301M | -203M | -216M |
| EBITDA | - | 260M | -192M | -204M | -174M | -181M |
| Net Income | 153M | 159M | -146M | -163M | -146M | -186M |
| EPS | 0.54 | 0.55 | -0.50 | -0.55 | -0.49 | -0.57 |
| Balance Sheet | ||||||
| Total Assets | 1.32B | 1.54B | 1.49B | 1.36B | 1.36B | 1.50B |
| Total Liabilities | 293M | 308M | 336M | 304M | 390M | 437M |
| Shareholders' Equity | 1.03B | 1.23B | 1.15B | 1.06B | 967M | 1.06B |
| Cash & Short-term Investments | 476M | 387M | 133M | 156M | 129M | 164M |
| Cash Flow | ||||||
| Operating Cash Flow | 245M | 277M | -43.9M | -109M | -131M | 25.8M |
| Capital Expenditure | 58.5M | 72.7M | 77.5M | 78.4M | 42.8M | 10.1M |
| Free Cash Flow | 186M | 205M | -121M | -187M | -174M | 15.6M |
| Ratios | ||||||
| ROE | 15.0% | 12.9% | -12.7% | -15.4% | -15.1% | -17.5% |
| ROA | 11.6% | 10.3% | -9.8% | -12.0% | -10.8% | -12.4% |
| Net Profit Margin | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% | -605.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ABCELLERA BIOLOGICS dividends
ABCELLERA BIOLOGICS has not paid dividends in the last 5 fiscal years.
Who owns ABCELLERA BIOLOGICS
- Insiders 21.74%
- Institutions 36.80%
- Public & others 41.47%
- Shares outstanding 327M
- Free float 209M
ABCELLERA BIOLOGICS company profile
- Company name
- ABCELLERA BIOLOGICS
- Ticker
- 8QQ.F
- ISIN
- CA00288U1066
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 562
- Fiscal year end
- December
- Address
- 150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6
- Phone
- 604 559 9005
- Website
- abcellera.com
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCELLERA BIOLOGICS management
10- Dr. Carl L.G. Hansen Ph.D.CEO, President & Chairperson · born 1975
- Mr. Andrew Booth M.B.A.Chief Financial Officer · born 1974
- Dr. Veronique Lecault Ph.D.CTO & Director · born 1985
- Mr. Tryn T. Stimart Esq., J.D., M.Sc.Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer · born 1970
- Mr. Andrew Knowles M.Sc.Vice President of Operations
- Marcie Thiessen B.Com., CPA, CGASenior Director of Finance & Accounting
- Mr. Martin Hogan M.Sc.Senior Director of Strategic Finance & IR
- Ms. Tiffany Chiu B.Sc., Ph.D.Vice President of Communications
- Mr. Murray McCutcheon Ph.D.Senior Vice President of Partnering
- Mr. Adam Clarke M.A.I.C.D., Ph.D.Senior Vice President of Discovery